Fig. 5
From: Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
Loss of PI3 kinase association improves the sensitivity of secondary mutations of KIT to Imatinib in vivo. 6 × 106 Ba/F3 cells stably expressing KIT mutant in PBS containing 10% Matrixgel were subcutaneously injected into right flank of nude mice. a The days of tumor formation were calculated. When the tumor size reaches 100 mm3 (W557K558del/V654A) or 300 mm3 (W557K558del/V654A/M724A), mice were treated with KIT inhibitor Imatinib (50 mg/kg) daily and/or PI3 kinase inhibitor Copanlisib (6 mg/kg) every other day for 10 days. After sacrifice, b, c the tumor size and weight were measured and tumor volume was calculated N = 4)